AGORA

Agora issue guide

Gender-affirming care for minors: what it is and why it's contested

By the Agora desk · Published · How we count player splits

Gender-affirming care for transgender young people ranges from social support, like a new name, to puberty blockers and hormones. Major U.S. medical groups support access; about half the states and several European health systems have restricted the medical treatments, citing weak evidence. In 2025 the Supreme Court upheld a state ban, and in 2026 federal Medicaid stopped paying for these treatments for minors.

Today's story · 22 November 2026

Lobby Market Winner: Fully release the Epstein files with only victims names redacted

Should the DOJ release all Epstein files with only victims' names redacted?

▶ Play today's story

Read the briefing first

Agora players, live

See all 2 player splits on this issue

Latest Agora stories on this issue

What the care involves

Before puberty, care is social and psychological: support from clinicians and, if the family chooses, a change of name, pronouns or clothes. Children who have not reached puberty are not given drugs or surgery.

At puberty, some young people with gender dysphoria are prescribed puberty blockers, which pause the body's changes, and later cross-sex hormones (testosterone or estrogen). Surgery on minors is uncommon. Most of the political fight is about blockers and hormones for teenagers.

What the evidence reviews found

Both sides cite evidence. The American Academy of Pediatrics, the Endocrine Society and other U.S. medical groups say this care, given carefully, eases distress, and that withholding it can harm young people.

Systematic reviews have rated the evidence on blockers and hormones as weak. England's independent Cass Review reached that conclusion in 2024, and the NHS stopped routinely prescribing puberty blockers for gender dysphoria. A 2025 review by the U.S. Department of Health and Human Services also questioned the benefits and argued for psychological support first. Supporters of care reply that much of paediatric medicine rests on similar evidence, and dispute the HHS review's conclusions.

What the law says now

Around 27 states ban this care for minors. In June 2025, in United States v. Skrmetti, the Supreme Court upheld Tennessee's ban 6–3. In August 2026 the federal government finalised a rule barring federal Medicaid and CHIP money for puberty blockers, hormones and surgery for minors; states and private insurers can still pay with their own money. Agora asked players whether the government should pay for gender-transition treatment for minors.

The same divide runs through sport, where states and leagues are deciding who can compete in girls' and women's events. Agora asked players whether transgender women should be allowed to play in the WNBA.

The case for access to gender-affirming care

  • Major U.S. medical groups say it is appropriate care, decided case by case by doctors, families and young people.
  • Transgender young people face high rates of depression and suicidal thoughts, and supporters say care eases that distress.
  • Puberty blockers pause changes that can be distressing and hard to undo, buying time to decide.
  • Politicians should not override parents and doctors on a family's medical decisions.

The case for restricting it

  • Systematic reviews in England and elsewhere found the evidence for blockers and hormones is weak.
  • Minors can't fully weigh lifelong effects such as on fertility, and some later stop identifying as transgender.
  • Many young people referred have other mental-health needs that should be addressed first.
  • England, Sweden and Finland have pulled back, so U.S. limits follow the evidence rather than politics.

Common questions

Is gender-affirming care for minors legal?

It depends on the state. About 27 states ban puberty blockers and hormones for transgender minors, and the Supreme Court upheld such a ban in 2025. Elsewhere it is legal, but federal Medicaid no longer pays for it.

Do children get surgery?

Children who haven't reached puberty get no medical treatment, only social and psychological support. Surgery on minors is uncommon; the debate is mainly about puberty blockers and hormones for teenagers.

What did the Cass Review find?

The 2024 independent review for NHS England found the evidence for puberty blockers and hormones in young people was weak and called for a more cautious, holistic approach. England then stopped routinely prescribing puberty blockers for gender dysphoria.

Key facts and sources

What Agora players think

The side players picked before playing each story. Live from Agora games, not a scientific poll.

Every Agora story on this issue

More on Health

Today's story · 22 November 2026

Lobby Market Winner: Fully release the Epstein files with only victims names redacted

Should the DOJ release all Epstein files with only victims' names redacted?

▶ Play today's story

Read the briefing first

Written by the Agora team from the sources above. Player numbers update as people play.